{"id":"artesunate-sulfamethoxypyrazine-pyrimethamine","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, vomiting, diarrhea)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Hematologic effects (anemia, thrombocytopenia)"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL361497","moleculeType":"Small molecule","molecularWeight":"384.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artesunate is an artemisinin derivative that generates reactive oxygen species and damages parasite proteins and membranes. Sulfamethoxypyrazine and pyrimethamine are antifolate agents that inhibit dihydrofolate reductase and other enzymes in the folate synthesis pathway, preventing nucleotide production necessary for parasite DNA replication. The combination provides synergistic antimalarial activity through complementary mechanisms.","oneSentence":"This combination drug uses artesunate to disrupt malaria parasite metabolism while sulfamethoxypyrazine and pyrimethamine inhibit folate synthesis pathways essential for parasite survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:30.929Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria (Plasmodium falciparum infection)"}]},"trialDetails":[{"nctId":"NCT01054651","phase":"PHASE3","title":"A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni","status":"COMPLETED","sponsor":"Kenya Medical Research Institute","startDate":"2009-10","conditions":"Schistosoma Mansoni","enrollment":212},{"nctId":"NCT00484900","phase":"PHASE3","title":"Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria","status":"COMPLETED","sponsor":"Dafra Pharma","startDate":"2006-05","conditions":"Plasmodium Falciparum Malaria","enrollment":1390},{"nctId":"NCT00510159","phase":"PHASE2, PHASE3","title":"Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis","status":"COMPLETED","sponsor":"Dafra Pharma","startDate":"2007-08","conditions":"Schistosoma Haematobium","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Co-arinate FDC"],"phase":"phase_3","status":"active","brandName":"Artesunate+Sulfamethoxypyrazine/pyrimethamine","genericName":"Artesunate+Sulfamethoxypyrazine/pyrimethamine","companyName":"Kenya Medical Research Institute","companyId":"kenya-medical-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug uses artesunate to disrupt malaria parasite metabolism while sulfamethoxypyrazine and pyrimethamine inhibit folate synthesis pathways essential for parasite survival. Used for Malaria (Plasmodium falciparum infection).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}